Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + tremelimumab + Yttrium-90 radioembolisation
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intra-arterial
01
Overview
durvalumab + tremelimumab + Yttrium-90 radioembolisation is a combination therapy regimen being evaluated by The University of Hong Kong for the treatment of metastatic hepatocellular carcinoma (HCC). The regimen consists of two immune checkpoint inhibitors developed by AstraZeneca—durvalumab (an anti-PD-L1 monoclonal antibody) and tremelimumab (an anti-CTLA-4 monoclonal antibody)—alongside Yttrium-90 (Y90) radioembolisation, a form of selective internal radiation therapy (SIRT). This triple combination aims to leverage the synergistic potential of dual checkpoint blockade and localized radiation to induce an abscopal effect, enhancing systemic anti-tumor immunity in patients with previously untreated advanced disease. The clinical trial (NCT05809869) utilizes a priming dose of immunotherapy followed by Y90 administration to optimize the immune-priming effects of radiation.
- Other names
- durvalumab + tremelimumab + Y90Durvalumab, Tremelimumab and Radioembolisation in Metastatic HCC
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on durvalumab + tremelimumab + Yttrium-90 radioembolisation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + tremelimumab + Yttrium-90 radioembolisation.